ONYX PHARMACEUTICALS INC 4

4 · ONYX PHARMACEUTICALS INC · Filed Aug 8, 2013

Form 4

Period: 2013-08-07

SVP, General Counsel

Transactions

Exercise/Conversion
Stock Option (Right to Buy)
2013-08-07−1,215→ 13,686 total
Exercise: $32.07Exp: 2019-08-31→ Common Stock (1,215 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2013-08-07−796→ 25,466 total
Exercise: $37.68Exp: 2022-03-29→ Common Stock (796 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2013-08-07−802→ 16,042 total
Exercise: $35.18Exp: 2021-03-31→ Common Stock (802 underlying)
Exercise/Conversion
Common Stock
2013-08-07$37.68/sh+796$29,993→ 37,868 total
Sale
Common Stock
2013-08-07$131.86/sh−4,052$534,297→ 34,618 total
Exercise/Conversion
Common Stock
2013-08-07$32.07/sh+1,215$38,965→ 35,833 total
Exercise/Conversion
Common Stock
2013-08-07$37.68/sh+583$21,967→ 37,072 total
Exercise/Conversion
Stock Option (Right to Buy)
2013-08-07−656→ 5,250 total
Exercise: $30.28Exp: 2020-03-31→ Common Stock (656 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2013-08-07−583→ 18,667 total
Exercise: $37.69Exp: 2022-03-29→ Common Stock (583 underlying)
Exercise/Conversion
Common Stock
2013-08-07$35.18/sh+802$28,214→ 38,670 total
Exercise/Conversion
Common Stock
2013-08-07$30.28/sh+656$19,864→ 36,489 total

Footnotes (4)

[F1]Shares sold pursuant to a 10b5-1 plan.
[F2]Twenty-Five percent of the shares subject to the option vest and become exercisable one year from the date of grant and vest and beceome exercisable at a rate of 1/48th per month thereafter.
[F3]12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.
[F4]The shares vest monthly from the date of grant at a rate of 1/48th per month over a period of 48 months

Documents

1 file